TY - JOUR AU - Klein, R. AU - Moss, S. E. AU - Meuer, S. M. AU - Klein, B. E. PY - 2008 DA - 2008// TI - The 15-year cumulative incidence of retinal vein occlusion: the Beaver Dam Eye Study JO - Arch Ophthalmol. VL - 126 UR - https://doi.org/10.1001/archopht.126.4.513 DO - 10.1001/archopht.126.4.513 ID - Klein2008 ER - TY - JOUR AU - Haymore, J. G. AU - Mejico, L. J. PY - 2009 DA - 2009// TI - Retinal vascular occlusion syndromes JO - Int Ophthalmol Clin. VL - 49 UR - https://doi.org/10.1097/IIO.0b013e3181a8db88 DO - 10.1097/IIO.0b013e3181a8db88 ID - Haymore2009 ER - TY - JOUR AU - Encke, A. PY - 1977 DA - 1977// TI - Pathophysiology of venous thrombosis (author’s transl) JO - Langenbecks Arch Chir VL - 345 UR - https://doi.org/10.1007/BF01305498 DO - 10.1007/BF01305498 ID - Encke1977 ER - TY - JOUR AU - Rehak, M. AU - Wiedemann, P. PY - 2010 DA - 2010// TI - Retinal vein thrombosis: pathogenesis and management JO - J Thromb Haemost VL - 8 UR - https://doi.org/10.1111/j.1538-7836.2010.03909.x DO - 10.1111/j.1538-7836.2010.03909.x ID - Rehak2010 ER - TY - JOUR AU - Deobhakta, A. AU - Chang, L. K. PY - 2013 DA - 2013// TI - Inflammation in retinal vein occlusion JO - Int J Inflam VL - 2013 UR - https://doi.org/10.1155/2013/438412 DO - 10.1155/2013/438412 ID - Deobhakta2013 ER - TY - JOUR AU - Campochiaro, P. A. PY - 2013 DA - 2013// TI - Vascular endothelial growth factor promotes progressive retinal nonperfusion in patients with retinal vein occlusion JO - Ophthalmology VL - 120 UR - https://doi.org/10.1016/j.ophtha.2012.09.032 DO - 10.1016/j.ophtha.2012.09.032 ID - Campochiaro2013 ER - TY - JOUR AU - Thach, A. B. PY - 2014 DA - 2014// TI - Time to clinically significant visual acuity gains after ranibizumab treatment for retinal vein occlusion: BRAVO and CRUISE trials JO - Ophthalmology VL - 121 UR - https://doi.org/10.1016/j.ophtha.2013.11.022 DO - 10.1016/j.ophtha.2013.11.022 ID - Thach2014 ER - TY - JOUR AU - Bressler, N. M. AU - Schachat, A. P. PY - 2010 DA - 2010// TI - Management of macular edema from retinal vein occlusions: you can never have too many choices JO - Ophthalmology VL - 117 UR - https://doi.org/10.1016/j.ophtha.2010.03.037 DO - 10.1016/j.ophtha.2010.03.037 ID - Bressler2010 ER - TY - JOUR AU - Campochiaro, P. A. PY - 2015 DA - 2015// TI - Intravitreal aflibercept for macular edema following branch retinal vein occlusion: the 24-week results of the VIBRANT Study JO - Ophthalmology VL - 122 UR - https://doi.org/10.1016/j.ophtha.2014.08.031 DO - 10.1016/j.ophtha.2014.08.031 ID - Campochiaro2015 ER - TY - JOUR AU - Papadopoulos, N. PY - 2012 DA - 2012// TI - Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab JO - Angiogenesis VL - 15 UR - https://doi.org/10.1007/s10456-011-9249-6 DO - 10.1007/s10456-011-9249-6 ID - Papadopoulos2012 ER - TY - JOUR AU - Holash, J. PY - 2002 DA - 2002// TI - VEGF-Trap: a VEGF blocker with potent antitumor effects JO - Proc Natl Acad Sci U S A VL - 99 UR - https://doi.org/10.1073/pnas.172398299 DO - 10.1073/pnas.172398299 ID - Holash2002 ER - TY - JOUR AU - Evoy, K. E. AU - Abel, S. R. PY - 2013 DA - 2013// TI - Aflibercept: newly approved for the treatment of macular edema following central retinal vein occlusion JO - Ann Pharmacother VL - 47 UR - https://doi.org/10.1345/aph.1R705 DO - 10.1345/aph.1R705 ID - Evoy2013 ER - TY - JOUR AU - Pfau, M. PY - 2015 DA - 2015// TI - Clinical outcome after switching therapy from ranibizumab and/or bevacizumab to aflibercept in central retinal vein occlusion JO - Ophthalmic Res VL - 54 UR - https://doi.org/10.1159/000439223 DO - 10.1159/000439223 ID - Pfau2015 ER - TY - JOUR AU - Papakostas, T. D. PY - 2016 DA - 2016// TI - Intravitreal aflibercept for macular oedema secondary to central retinal vein occlusion in patients with prior treatment with bevacizumab or ranibizumab JO - Eye (Lond) VL - 30 UR - https://doi.org/10.1038/eye.2015.175 DO - 10.1038/eye.2015.175 ID - Papakostas2016 ER - TY - JOUR AU - Freund, K. B. PY - 2015 DA - 2015// TI - Treat-and-extend regimens with anti-VEGF agents in retinal diseases: a literature review and consensus recommendations JO - Retina VL - 35 UR - https://doi.org/10.1097/IAE.0000000000000627 DO - 10.1097/IAE.0000000000000627 ID - Freund2015 ER - TY - JOUR AU - Gregori, N. Z. AU - Feuer, W. AU - Rosenfeld, P. J. PY - 2010 DA - 2010// TI - Novel method for analyzing snellen visual acuity measurements JO - Retina VL - 30 UR - https://doi.org/10.1097/IAE.0b013e3181d87e04 DO - 10.1097/IAE.0b013e3181d87e04 ID - Gregori2010 ER - TY - JOUR AU - Rogers, S. L. PY - 2010 DA - 2010// TI - Natural history of branch retinal vein occlusion: an evidence-based systematic review JO - Ophthalmology VL - 117 UR - https://doi.org/10.1016/j.ophtha.2010.01.058 DO - 10.1016/j.ophtha.2010.01.058 ID - Rogers2010 ER - TY - JOUR AU - Christoforidis, J. B. PY - 2012 DA - 2012// TI - Pharmacokinetic properties of intravitreal I-124-aflibercept in a rabbit model using PET/CT JO - Curr Eye Res VL - 37 UR - https://doi.org/10.3109/02713683.2012.727521 DO - 10.3109/02713683.2012.727521 ID - Christoforidis2012 ER - TY - JOUR AU - Fauser, S. AU - Schwabecker, V. AU - Muether, P. S. PY - 2014 DA - 2014// TI - Suppression of intraocular vascular endothelial growth factor during aflibercept treatment of age-related macular degeneration JO - Am J Ophthalmol VL - 158 UR - https://doi.org/10.1016/j.ajo.2014.05.025 DO - 10.1016/j.ajo.2014.05.025 ID - Fauser2014 ER -